SLC5A2 and chronic kidney disease: Ohara K. et al. [28] conducted a study of forty CKD patients with fluid retention, and the patients were divided into three groups treated with an SGLT-2 inhibitor (dapagliflozin), loop diuretic (furosemide), or vasopressin V2 receptor antagonist (tolvaptan).